Eli Lilly (LLY) Deferred Taxes (2009 - 2026)

Eli Lilly has reported Deferred Taxes for 18 years, with the latest figure at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 277.04% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $2.8 billion (changed 0.11% YoY), and the FY2025 full-year result was $1.7 billion, down 36.38% from the prior year.
• Deferred Taxes for Q1 2026 stood at $1.5 billion, up from $748.1 million in the prior quarter.
• The five-year high for Deferred Taxes was $1.5 billion in Q1 2026, with the low at -$501.4 million in Q3 2025.
• Historically, Deferred Taxes has averaged $611.4 million across 5 years, with a median of $559.4 million in 2023.
• Annual changes were most pronounced in 2023 — Deferred Taxes soared 4967.31% — and 2025, when it sank 216.66%.
• Eli Lilly's Deferred Taxes stood at -$10.4 million in 2022, then soared by 4967.31% to $506.2 million in 2023, then jumped by 90.95% to $966.6 million in 2024, then declined by 22.61% to $748.1 million in 2025, then surged by 97.57% to $1.5 billion in 2026.
• The last three Deferred Taxes figures came in at $1.5 billion (Q1 2026), $748.1 million (Q4 2025), and -$501.4 million (Q3 2025), per Business Quant data.